Title : A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.

Pub. Date : 2021 Nov 22

PMID : 34811370






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-label phase I/II clinical trial (TBCOX2, NCT02503839). Etoricoxib prostaglandin-endoperoxide synthase 2 Homo sapiens